Foundation for Angelman Syndrome Therapeutics

04/04/2026

Sometimes all it takes is one idea. 💙

On International Angelman Day, Beth Phillips Synk and Laura Foglyano hosted Pinball with a Purpose: Immy’s International Angelman Day Bash, a first-time fundraiser that raised more than $33,000 for FAST.

More than that, they created something full of love, generosity, and shared purpose, bringing together friends, family, and seven Angelman syndrome families from multiple states.

Beth and Laura, thank you for your heart, your leadership, and the beautiful impact you made. We are so proud to celebrate you both. 💙

Learn how Beth started small and took a chance at something bigger: https://cureangelman.org/articles/immy-pinball-with-a-purpose-angelman-fundraiser

04/03/2026

ASF and FAST are incredibly proud of the Angelman syndrome community for your advocacy efforts to start off 2026. Catch the full recap, successes, and what’s next after our 2026 AS Congressional Advocacy Day in Washington, D.C. – an impactful day where 138 advocates representing 37 states participated in 139 congressional meetings!

And to build off the momentum of our federal efforts, we now have Medicaid resources to help families navigate the changes happening at the state level.

Read the updates and find Medicaid resources here: https://buff.ly/7aNxAiD

03/30/2026

Today, we are sharing a disappointing update from the Roche/Genentech regarding the discontinuation of the alogabat program for Angelman syndrome. We encourage you to read the full letter from Roche/Genentech for additional information and context.

Thank you to everyone who participated in this trial. Your commitment is meaningful and continues to move research forward.

Read the full letter: https://bit.ly/Alogabat-Letter-March-2026

03/21/2026

FAST Poland - Foundation for Angelman Syndrome Therapeutics hosted its second nationwide Angelman syndrome conference, bringing together families, caregivers, clinicians, therapists, and researchers for an important day of learning, connection, and shared purpose.

This year’s theme, “From Diagnosis to Therapy,” reflected a critical truth: progress depends not only on scientific discovery, but also on earlier diagnosis, stronger systems, real-world access, and community support.

It was an important day for the Polish Angelman syndrome community and a reminder of the power of collaboration in shaping a better future.

Read the full recap: https://buff.ly/Et2IAOq

03/19/2026

Tonight, we’ll be watching CNBC Cures: Defying Rare Disease.

We’ll be watching for the stories that show what families face every day.
We’ll be watching for the science pushing the field forward.
And we’ll be watching for the bigger conversation rare disease needs more of: how we close the gaps in funding, access, and support that still stand between progress and patients.

This matters far beyond any one condition.

Rare disease families know that visibility matters. So does urgency. We’re glad to see this conversation reach a broader audience tonight at 7 p.m. ET on CNBC.

Hosted by Becky Quick, CNBC will debut an in-depth, one-hour special, “CNBC Cures: Defying Rare Disease,” spotlighting the families dealing with rare diseases and the scientists, advocates, and innovators fighting to change their futures. 'CNBC Cures: Defying Rare Disease' airs tonight, March 19...

03/18/2026

If your loved one was diagnosed with Angelman syndrome, you may be feeling overwhelmed, uncertain, and full of questions.

You are not alone 💙

FAST is here to help parents, caregivers, grandparents, and family members find trusted information, connection, and a path forward.

Whether you are looking for reliable resources, answers to common questions, or a community that understands, we invite you to connect with us.

Start here: https://cureangelman.org/newly-diagnosed

03/11/2026

New research strengthens evidence for ORCA, a caregiver-reported tool designed to measure communication in Angelman syndrome, and shows it aligns with widely used and validated developmental and adaptive behavior measures.

Find out more and why this matters: https://buff.ly/Bc4jRgr

03/06/2026

In case you missed the CNBC Cures livestream on Tuesday, you can watch Dr. Allyson Berent and Mike Hanrahan talk about why FAST exists and what our venture philanthropy model is really built to do: not just fund research, but push the work forward with urgency and discipline, so progress can reach our loved ones.

Watch the recording: https://buff.ly/HtOaSc0

03/05/2026

Big news: Team Kick-AS is heading to the 2026 TCS New York City Marathon! 🗽🏃

We’re thrilled to share that for the first time ever, FAST is an official charity partner of this iconic race! We have a very limited number of bibs available--first-come, first-serve--and would love for you join Team Kick-AS to run the five Boroughs with us!

If you secured a bib through the official New York Road Runners drawing, this is the perfect opportunity to dedicate your miles to raising critical funds for Angelman syndrome research.

Learn more and join Team Kick-AS: https://buff.ly/LDmPA8p

03/04/2026

Today marks our 3rd AS Congressional Advocacy Day, where over 150 Angelman advocates take to Capitol Hill to meet with their elected officials. Through personal stories and a united voice, they are having meaningful conversations and making specific legislative requests to ensure Angelman syndrome remains a priority in the U.S. Congress – a federal effort!

JOIN US: We urge families, friends, researchers, and clinicians to amplify our voices by reaching out to your congressional leaders in support of the in-person advocacy happening right now on Capitol Hill!

Take action in 4 easy step to send the same united message to your elected officials:
1️⃣https://bit.ly/2026advocacydayasks
2️⃣Enter your address
3️⃣Put your name, relationship to AS and address in the closing
4️⃣Click “Send It!”

Our 2026 priorities include:
• Asking the Department of Defense (DOD) to continue to include Angelman syndrome as an eligible condition for funding,
• While urging FDA and NIH to prioritize and fund patient-informed, gene-targeted, and real‑world data efforts that accelerate development and evaluation of Angelman therapies

03/03/2026

This is a big week for Angelman syndrome patient-led advocacy.

Today in NYC, FAST leaders Dr. Allyson Berent and Mike Hanrahan will join Becky Quick at the CNBC Cures Summit to discuss the evolving role of patient-led advocacy in rare disease.

Also today in Washington, DC, FAST and ASF are gearing up for Congressional Advocacy Day with a simple goal: show up with voices from across the country, build relationships with congressional offices, and turn more lawmakers into champions for Angelman syndrome.

Different rooms, same goal: making sure families are part of the decisions that shape research, regulation, and access.

03/02/2026

Tomorrow, FAST will join one of the most important rare disease conversations happening this year.

The first-ever CNBC Cures Summit is bringing together leaders across biotech, investment, and policy to focus on what it will take to accelerate the future of medicine in rare disease.

FAST leaders Dr. Allyson Berent and Mike Hanrahan will join Becky Quick for a featured conversation, From Awareness to Action, on how FAST’s venture philanthropy model has helped move beyond awareness to actively fund, coordinate, and accelerate research and clinical development in Angelman syndrome.

FAST will bring a patient- and family-led perspective grounded in ex*****on: the outcomes, shared tools, and trial readiness that help reduce friction and move therapeutic development forward.

Register to watch the free livestream: https://bit.ly/4cinix3